RLYB - Rallybio Corp Market Valuation

The price chart on GURU.Markets shows the market capitalization of Rallybio Corporation (RLYB), which stands at 0.08. Rallybio Corporation is implementing AI and robotics to accelerate the discovery of treatments for orphan diseases by automating molecular screening. The business's success relies on test safety data and R&D funding. Patent protection and FDA status create high barriers to entry, ensuring high returns upon therapy approval.

Rallybio Corp - RLYB Market Value (period 07/04/2022 - 11/15/2026)

Comprehensive metric breakdowns and analytics for Rallybio (RLYB)

- market price and analyst price targets:

Price Chart Rallybio Corp.|RLYB - Price Target Chart

- market capitalization statistics:

Market Valuation Rallybio Corporation|RLYB - Total Enterprise Value

- business book valuation details:

Book Value per Share Rallybio|RLYB - Company Book Value|Market Value to Book Value Ratio rallybio.com|RLYB - Total Asset Value of Company

- debt and liquidity data:

- financial results and valuation multiples details:

RLYB - Net Profit|Future Profit Rallybio Corporation|RLYB - Company Value to Net Income|Future Price to Earnings Rallybio|RLYB - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Rallybio Corporation|RLYB - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Rallybio|RLYB - Earnings per share for the trailing year|Quarterly EPS earnings growth rallybio.com|RLYB - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Rallybio Corporation

- sales revenue and business income indicators:

RLYB - Company Sales Revenue|Company Projected Revenue Rallybio Corporation|RLYB - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple Rallybio

Fundamental company analysis:RLYB (Rallybio)

Market capitalization stability determines the long-term resilience of Rallybio Corporation (RLYB) for a strategic investor. This metric reflects the market valuation of the business as the product of the current share price and the total number of shares outstanding. The trend in the total value of all issuer shares visualizes shifts in market confidence in the assets. For the biotechnology sector, this indicator measures expectations regarding the success of clinical developments. In the case of orphan drugs, capitalization reflects the potential to monetize the scarce demand for rare medicines.

Key competitors